Moderate to Severe Acute Pain Clinical Trial
Official title:
A Multicenter,Randomized, Double-blind, Dose Ranging , Active- and Placebo-controlled, Parallel Groups, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR18042 Tablets for the Treatment of Postoperative Pain of Impacted Tooth.
| Verified date | March 2021 |
| Source | Jiangsu HengRui Medicine Co., Ltd. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study was to evaluate the Efficacy and safety of HR18042 tablets for the Treatment of Post-surgical Pain After extraction of impacted tooth, find the optimal dose.
| Status | Active, not recruiting |
| Enrollment | 187 |
| Est. completion date | April 23, 2021 |
| Est. primary completion date | January 25, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility | Inclusion Criteria: 1. 18 to 75 years old. 2. Subjects must have a plan of extraction of impacted tooth. 3. Subjects with moderate to severe pain (VAS score = 50mm).This must be measured within a maximum of 4 hours after the end of extraction of impacted tooth. 4. weight at least 45kg,and no more than 100kg. 5. If a female is of child-bearing potential, she must be using highly effective methods of contraception throughout the study. 6. Willingness to comply with the study procedures and requirements. 7. willing and able to provide written informed consent for this study. Exclusion Criteria: 1. any analgesic medication other than preoperative or intraoperative anaesthetic agents within 12h before taking trial medication medication 2. a longacting NSAID within 4 days,or a shortacting NSAID within 1 days prior to dosing. 3. any anti-depressive medication, selective serotonin reuptake inhibitors (SSRIs), diet pills et.al. with 30 days of study entry. 4. Oral surgical site combined with infection. 5. Severe cardiovascular and cerebrovascular diseases. 6. Severe gastrointestinal disease. 7. had a history of seizures or drug or alcohol abuse. 8. uncontrolled hypertension. 9. significant abnormal electrocardiogram 10. significant abnormal laboratory value. 11. Allergic to the study drug and ingredients. 12. Pregnancy, lactation or recent Pregnant plan; 13. Subjects who participated in a clinical research study involving an experimental drug before 30 days of study entry. 14. other conditions unsuitable for participation in the study. |
| Country | Name | City | State |
|---|---|---|---|
| China | West China Hospital of Stomatology Sichuan University | Chengdu | Sichuan |
| Lead Sponsor | Collaborator |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | the Sum of Pain Intensity Differences(SPID) | SPID is derived as the weighted Sum of Pain Intensity Differences (baseline pain - current pain), measured at different time points via the PI-VAS. Time between two consecutive measurements will be used for weighting. Larger values indicate larger pain relief. | 0-8hours | |
| Secondary | the Sum of Pain Intensity Differences(SPID) | 0-4hours | ||
| Secondary | the Sum of Pain Intensity Differences(SPID) | 0-12hours | ||
| Secondary | Pain Intensity Differences(PID) | Include pain intensity differences(PIDs) from baseline at each time point. measured at different time points via the PI-VAS. | 0-12hours | |
| Secondary | Pain relief(PAR) | pain relief (PAR) on a 5-point Likert scale (0, none, 1, a little, 2, some,3, a lot, 4, complete). | 0-12hours | |
| Secondary | the Sum of Pain relief Differences(SPAR) | SPAR is derived as the weighted Sum of Pain relief, measured at different time points via the 5-point Likert scale. Time between two consecutive measurements will be used for weighting. Larger values indicate larger pain relief. | 0-4hours | |
| Secondary | the Sum of Pain relief Differences(SPAR) | 0-8hours | ||
| Secondary | the Sum of Pain relief Differences(SPAR). | 0-12hours | ||
| Secondary | Subject who reaches a 30% reduction in pain intensity from baseline | 4hours?8hours?12hours | ||
| Secondary | Subject who reaches a 50% reduction in pain intensity from baseline | 4hours?8hours?12hours | ||
| Secondary | time to perceptible pain relief | 0-12hours | ||
| Secondary | time to meaningful pain relief | Patients used one stopwatch to record the time to 'perceptible' PAR and another stopwatch for the time to'meaningful' PAR.Patients started timing upon intake of study medication and stopped one stopwatch at the onset of perceptible PAR and another upon achieving meaningful PAR. | 0-12hours | |
| Secondary | Time to first use of rescue medication | 0-12hours | ||
| Secondary | Proportion of subjects who take of at least 1 dose of rescue medication | 0-12hours | ||
| Secondary | Subject's overall assessment of study medication | Patients made an overall assessment of the study medication using a verbal rating scale (excellent, verygood, good, fair, poor). | 12hours |